Firefighters receive £200k command unit with drone
The States of Jersey Fire Service said the five-tonne Mercedes Sprinter van would replace its currently command vehicle, which would be sold on once staff had been trained up.
The vehicle had been "designed to meet the [service's] needs", with swivel front seats so the crew can communicate, an external smart screen, and a 2.5m (8ft) awning creating an exterior workspace, a spokesperson said.
Station commander Adam Rogers said the high-tech vehicle was "flexible enough to be deployed throughout the island" and had been fitted with drone "for greater situational awareness".
Follow BBC Jersey on X and Facebook. Send your story ideas to channel.islands@bbc.co.uk.
Woman rescued from smoke-filled flat in Jersey
Fire and rescue service launches new website
Jersey firefighters get long-service awards
Jersey Fire and Rescue Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Mission to power ferries and boats with hydrogen power
A Jersey yachtsman hopes to reduce the maritime industry's emissions by using hydrogen power to fuel boats and ferries. Ocean racer Phil Sharp has used an £347,000 grant from the States of Jersey to develop a hydrogen-powered sailing boat. The plan now is for his company, OceansLab, to scale this sustainable technology to larger vessels, including ferries. "I have always been keen to push a new clean tech that we can adapt to the marine environment," he said. "This is the moment to try and kick-start the industry to demonstrate technologies that we can embrace for like inter-island ferries but also short sea shipping and longer-term, deep-sea shipping," he said. "My goal is to get this technology into real vessels and ships as quickly as possible in order to reduce the detrimental effect we are seeing from the maritime sector." OceanLab uses hydrogen fuel cells and solar panels. He said the company was currently trying to commercialise the technology in order to have a "greater environmental impact" and has recently moved into a production centre to start creating and assembling the technology to use. Mr Sharp also said the company has been visiting schools to teach them about clean energy on the island. More news stories for Jersey Listen to the latest news for Jersey Follow BBC Jersey on X and Facebook. Send your story ideas to Related internet links OceansLab
Yahoo
6 days ago
- Yahoo
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion
Chairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial Results Vancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (the "Company"), a clinical-stage biotechnology company developing innovative therapies for spinal cord injury (SCI) and other nervous system disorders, today announced a leadership transition as the Company enters the next phase of development for its first and potential best-in-class candidate, NVG-291. President and Chief Executive Officer Mike Kelly has stepped down as a director and officer of the Company and Dr. Adam Rogers, Chair of the Board and representative of NervGen's largest shareholder, has been appointed Interim CEO. "We are deeply grateful to Mike for his exceptional leadership during a pivotal time for NervGen," said Dr. Adam Rogers, Chairman and Interim CEO of NervGen. "Under Mike's guidance, the Company advanced NVG-291 through landmark proof-of-concept topline results from the chronic cohort of the CONNECT SCI study. Mike's leadership established the organizational framework needed for future growth and set a clear strategic direction to position NervGen one step closer to addressing its mission of transforming the lives of individuals living with spinal cord injury." "The chronic cohort of the CONNECT SCI study represents the strongest signal of efficacy observed to date in spinal cord injury," Dr. Rogers added. "We are entering the most exciting and important phase in NervGen's history and are committed to proactively engaging with regulators and the SCI community to advance NVG-291 toward its full potential." Regarding his departure, Mr. Kelly commented, "It's been an honor to lead NervGen during a pivotal time of clinical and operational growth. I'm proud of the team we've built and the opportunity to successfully advance NVG-291 through an unprecedented proof-of-concept efficacy trial in chronic spinal cord injury. With positive data in hand, NervGen is well-positioned for future growth. I remain a strong advocate of the Company and its mission to redefine the standard of care in spinal cord injury." The leadership transition comes as NervGen continues to analyze data from the chronic cohort of the CONNECT SCI study in preparation for sharing additional insights and engaging in regulatory discussions. About NVG-291NervGen holds exclusive worldwide rights to NVG-291, a first- and potential best-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology is licensed from Case Western Reserve University and is based on academic studies that demonstrated the preclinical efficacy of NVG-291-R, the rodent variant of NVG-291, in animal models of spinal cord injury. These studies implicated multiple potential molecular and cellular mechanisms by which NVG-291-R promotes neurorepair and functional improvement in both central and peripheral nervous system injury models. The implicated mechanisms include the promotion of neuronal sprouting, or plasticity, remyelination, and promotion of a non-inflammatory phenotype in the microglial cells. NervGen has received Fast Track designation from the FDA and Orphan Designation from the EMA for NVG-291 in individuals with spinal cord injury. About NervGenNervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotechnology company dedicated to developing innovative therapies to promote nervous system repair in settings of neurotrauma and neurologic disease. The Company is testing the clinical efficacy of its lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study clinical trial in spinal cord injury. Topline data from the chronic cohort (1-10 years post-injury) of this trial showed that NVG-291 met its primary endpoint and demonstrated strong trends in functional assessments. Continued analysis of data from the chronic cohort is ongoing. Enrollment in the subacute cohort (20-90 days post-injury) of the trial continues, and more information about participation in the subacute study is available at In addition, the company has initiated preclinical testing of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information about NervGen, visit and follow NervGen on X and LinkedIn for the latest news on the company. ContactsHuitt Tracey, Investor Relations htracey@ Bill Adams, Chief Financial Officer info@ Christy CurranSam Brown Healthcare Communications christycurran@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the Company's potential best-in-class candidate, NVG-291; the future growth of the Company; the Company's mission of transforming the lives of individuals living with spinal cord injury; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and study design of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury; the future development plans and benefits of NVG-291; the development plans and prospective target indications for NVG-300; and the creation of neuroreparative therapeutics to promote nervous system repair in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: our ability to obtain future funding on favorable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
10-07-2025
- Yahoo
New pedestrian-priority route planned in St Helier
A new pedestrian-priority route is to be created in St Helier. The government's Infrastructure and Environment (I&E) department said the continuous walkway would be created across the King Street and New Street junction. Minister for Infrastructure Constable Andy Jehan said the previous traffic arrangements on New Street and New Cut would be changed for an initial 12-month trial period. The main change would be the removal of access across Kind Street for buses and taxis, along with a minor alteration to permitted access times for commercial unloading, he said. More news stories for Jersey Listen to the latest news for Jersey I&E said a recent traffic survey showed during core retail hours about 50% of vehicles using the route were taxis and 8% were buses. Jehan said removing access to these vehicles would support pedestrian safety and reduce congestion. Only pedal cycles and essential commercial deliveries between 20:00 GMT and 10:00 will be permitted to cross King Street via New Cut under the scheme. New taxi rank locations were being sought in town, he said, but the rank at Library Place would remain. Jehan said the number of blue badge car parking spaces would not be affected and a map of blue badge spaces across the island would soon be issued. A more in-depth look at the work on New Street would be published shortly, he added. Follow BBC Jersey on X and Facebook. Send your story ideas to Disabled parking fears as street plans revealed New options considered for narrow St Helier road Government of Jersey
